Alternative Payment Plan Works Only With Large Patient CohortsSeptember 11th 2015
The experiment with bundled care in oncology is moving forward despite mixed results and lingering concerns about the administrative difficulty of implementation, potential care compromises, and whether innovation can thrive under fixed payments.
Alternative Payment Plan Focuses on Relevant Clinical OutcomesSeptember 8th 2015
As long as bundles are tied to a desired clinical outcome of relevance to the patients, we can truly move toward value-based medicine and enable the Goldilocks formula of delivery: just the right amount of care, not too much, and not too little-every time.
Necitumumab Assigned "Low Value" in Lung Cancer by Emory and Georgia TechAugust 28th 2015
New drug candidate necitumumab, which is being reviewed by the FDA as a treatment for patients with locally advanced or metastatic squamous non-small cell lung cancer, received a low cost-effectiveness evaluation in a study published in JAMA Oncology.
NCCN Strives to Control Cost of Cancer Drugs With New Evaluation FrameworkAugust 25th 2015
As cancer drugs soar in price, the National Comprehensive Cancer Network is introducing cost as a measure of the overall value of a therapy, following the trail of ASCO and a doctor from Memorial Sloan Kettering Cancer Center in attempting to put a lid on drug inflation.